Standards & Regulation

Is waiving patents for COVID-19 vaccines the right step forward?

A report suggests that more needs to be done to combat bleeding disorders. Is pharma playing its part in addressing this issue?

The EMA is looking for individuals to join its scientific advisory groups.

AAM calls for policies in the US that encourage greater use of biosimilars.

Fake COVID-19 treatments and vaccines are abound – but the FDA is on the case.

What progress is being made in the development of novel drugs in neuroscience?

Mexico’s Customs and Armed Forces have seized a fake batch of the Sputnik V COVID-19 vaccine.

Craig Burton from the AAM says patients must be able to access generics and biosimilars.

Is pharma now ushering in a new era of precision in neuroscience R&D?

How can the FDA tackle the inspection backlog?